BRPI0924302A2 - métodos de reduzir a proliferação e a viabilidade de agentes microbianos - Google Patents

métodos de reduzir a proliferação e a viabilidade de agentes microbianos

Info

Publication number
BRPI0924302A2
BRPI0924302A2 BRPI0924302A BRPI0924302A BRPI0924302A2 BR PI0924302 A2 BRPI0924302 A2 BR PI0924302A2 BR PI0924302 A BRPI0924302 A BR PI0924302A BR PI0924302 A BRPI0924302 A BR PI0924302A BR PI0924302 A2 BRPI0924302 A2 BR PI0924302A2
Authority
BR
Brazil
Prior art keywords
viability
methods
microbial agents
reducing proliferation
proliferation
Prior art date
Application number
BRPI0924302A
Other languages
English (en)
Inventor
Kroon Henk-Andre
Summerton Linda
Henry William
Original Assignee
Targeted Delivery Tech Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41460484&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0924302(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Targeted Delivery Tech Limited filed Critical Targeted Delivery Tech Limited
Publication of BRPI0924302A2 publication Critical patent/BRPI0924302A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
BRPI0924302A 2009-02-05 2009-07-23 métodos de reduzir a proliferação e a viabilidade de agentes microbianos BRPI0924302A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15028809P 2009-02-05 2009-02-05
PCT/US2009/051593 WO2010090654A1 (en) 2009-02-05 2009-07-23 Methods of reducing the proliferation and viability of microbial agents

Publications (1)

Publication Number Publication Date
BRPI0924302A2 true BRPI0924302A2 (pt) 2019-09-24

Family

ID=41460484

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0924302A BRPI0924302A2 (pt) 2009-02-05 2009-07-23 métodos de reduzir a proliferação e a viabilidade de agentes microbianos

Country Status (19)

Country Link
US (2) US20100197621A1 (pt)
EP (1) EP2393480A1 (pt)
JP (1) JP2012516889A (pt)
KR (1) KR20110128283A (pt)
CN (1) CN102368998A (pt)
AU (1) AU2009339445A1 (pt)
BR (1) BRPI0924302A2 (pt)
CA (1) CA2751412A1 (pt)
CO (1) CO6410285A2 (pt)
CR (1) CR20110409A (pt)
EC (1) ECSP11011246A (pt)
IL (1) IL214331A0 (pt)
MX (1) MX2011008204A (pt)
NI (1) NI201100152A (pt)
PE (1) PE20120326A1 (pt)
RU (1) RU2011136624A (pt)
SG (1) SG173183A1 (pt)
WO (1) WO2010090654A1 (pt)
ZA (1) ZA201105758B (pt)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090175810A1 (en) 2008-01-03 2009-07-09 Gareth Winckle Compositions and methods for treating diseases of the nail
WO2011022707A1 (en) * 2009-08-21 2011-02-24 Henk-Andre Kroon Vesicular formulations
JP2013532131A (ja) 2010-05-19 2013-08-15 サンド・アクチエンゲゼルシヤフト ポサコナゾール中間体の製造
US9206146B2 (en) 2010-05-19 2015-12-08 Sandoz Ag Purification of posaconazole and of posaconazole intermediates
JP5956980B2 (ja) 2010-05-19 2016-07-27 サンド・アクチエンゲゼルシヤフト キラル化合物の調製の方法
US9040539B2 (en) 2010-05-19 2015-05-26 Sandoz Ag Process for the preparation of chiral triazolones
US8039494B1 (en) 2010-07-08 2011-10-18 Dow Pharmaceutical Sciences, Inc. Compositions and methods for treating diseases of the nail
US10307418B2 (en) * 2010-12-16 2019-06-04 Platform Brightworks Two, Ltd. Azole pharmaceutical formulations for parenteral administration and methods for preparing and using the same as treatment of diseases sensitive to azole compounds
EP2685820A4 (en) * 2011-03-15 2014-08-27 Thompson Cooper Lab Llc COMPOSITIONS AND METHODS FOR TREATING INFECTIONS
WO2012126966A2 (en) * 2011-03-21 2012-09-27 Gregor Cevc Optimised preparations of highly adaptable aggregates
HUE034480T2 (en) 2011-04-28 2018-02-28 Platform Brightworks Two Ltd Improved parenteral formulations of lipophilic pharmaceutical agents and methods for their preparation and use
CN103635465A (zh) 2011-06-16 2014-03-12 桑多斯股份公司 制备手性化合物的方法
WO2013043830A1 (en) * 2011-09-20 2013-03-28 Molecular Express, Inc. Nanoparticle formulations of poorly soluble compounds
KR101350442B1 (ko) * 2011-10-12 2014-01-15 김동진 클로르헥시딘을 함유하는 안정한 수용성 살균방부제 조성물
WO2013057208A1 (en) 2011-10-18 2013-04-25 Targeted Delivery Technologies Limited Compositions and methods for reducing the proliferation and viability of microbial agents
GB201205642D0 (en) 2012-03-29 2012-05-16 Sequessome Technology Holdings Ltd Vesicular formulations
CN102659734B (zh) * 2012-04-28 2014-07-16 山东大学 一种三烯抗生素的制备方法
CA2874797A1 (en) * 2012-06-14 2013-12-19 Sandoz Ag Pharmaceutical composition comprising crystalline posaconazole
WO2014062621A1 (en) * 2012-10-15 2014-04-24 Stc.Unm Treatment of autophagy-based disorders and related pharmaceutical compositions, diagnostic and screening assays and kits
US8815952B1 (en) 2013-03-15 2014-08-26 Carnell & Herzog, LLC Chlorhexadine antiseptic
JP6206907B2 (ja) * 2013-07-16 2017-10-04 株式会社ゲノム創薬研究所 抗菌活性促進剤及び該抗菌活性促進剤を含有する感染症治療薬
CN110433291B (zh) * 2013-10-03 2023-04-28 博世健康爱尔兰有限公司 稳定的艾菲康唑组合物
CA3052643A1 (en) 2013-11-22 2015-05-28 Bausch Health Ireland Limited Anti-infective methods, compositions, and devices
CN103690543B (zh) * 2013-12-24 2015-09-09 广西医科大学 杀死烟曲霉菌的组合物及方法
MX2018000021A (es) 2015-06-30 2018-03-15 Sequessome Tech Holdings Limited Composiciones multifasicas.
CN106546668A (zh) * 2015-09-22 2017-03-29 陕西合成药业股份有限公司 一种分离福司氟康唑或其药用盐有关物质的hplc方法
CN106890167A (zh) * 2015-12-17 2017-06-27 中国科学院上海巴斯德研究所 一种具有抗结核活性的化合物及其应用
CN108472505A (zh) * 2015-12-22 2018-08-31 3M创新有限公司 用于孢子移除的方法
KR101749687B1 (ko) 2016-04-25 2017-06-21 경북대학교 산학협력단 7,10-에폭시옥타데카-7,9-다이에노산을 유효성분으로 포함하는 항균 조성물
KR101792239B1 (ko) 2016-11-01 2017-10-31 경북대학교 산학협력단 7,10-에폭시옥타데카-7,9-다이에노산 및 항생제를 유효성분으로 포함하는 항균 조성물
WO2017188692A1 (ko) * 2016-04-25 2017-11-02 경북대학교 산학협력단 7,10-에폭시옥타데카-7,9-다이에노산을 유효성분으로 포함하는 항균 조성물
CN107184551B (zh) * 2017-06-09 2020-09-01 甘肃新天马制药股份有限公司 一种利拉萘酯双粒径分布乳剂及其制备方法
CN112791048B (zh) * 2020-12-31 2023-01-17 海南海神同洲制药有限公司 一种硝酸舍他康唑栓及其制备方法
CN112931213B (zh) * 2021-03-29 2022-05-27 东北林业大学 一种杨树外植体脱毒试剂、脱毒方法及应用
CN114432297B (zh) * 2022-02-07 2022-10-11 中国人民解放军军事科学院军事医学研究院 Zaragozic acid A在产气荚膜梭菌Epsilon毒素中毒救治中的应用
CN115644062B (zh) * 2022-11-03 2023-11-17 天津科润农业科技股份有限公司 一种提高难出胚大白菜胚诱导率的培养基及其方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6348214A (ja) * 1986-08-18 1988-02-29 Morishita Seiyaku Kk １−〔２−（２，４−ジクロロフエニル）−３−メチル−１−ペンテニル〕−１ｈ−イミダゾ−ルを含有する水中油型脂肪乳剤
US6165500A (en) * 1990-08-24 2000-12-26 Idea Ag Preparation for the application of agents in mini-droplets
GB9111611D0 (en) * 1991-05-30 1991-07-24 Sandoz Ltd Liposomes
US5536729A (en) * 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
DE4336434A1 (de) * 1993-10-26 1995-04-27 Hoechst Ag Pharmazeutische Zubereitung für die parenterale, enterale und dermale Verabreichung von praktisch unlöslichen Arzneistoffen und Verfahren zu ihrer Herstellung
AU3257397A (en) * 1996-06-07 1998-01-07 Gist-Brocades B.V. Antifungal compositions
EP0872229A1 (en) * 1997-04-14 1998-10-21 Janssen Pharmaceutica N.V. Compositions containing an antifungal and a phospholipid
JP2002516267A (ja) * 1998-05-29 2002-06-04 アールティーピー・ファーマ・インコーポレーテッド 熱的に保護された微粒子組成物及びその最終蒸気滅菌
US20030215493A1 (en) * 2002-04-30 2003-11-20 Patel Pravin M. Composition and method for dermatological treatment
US6846837B2 (en) * 2002-06-21 2005-01-25 Howard I. Maibach Topical administration of basic antifungal compositions to treat fungal infections of the nails
US20040105881A1 (en) * 2002-10-11 2004-06-03 Gregor Cevc Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
CA2579805A1 (en) * 2004-09-03 2006-03-16 Piedmont Pharmaceuticals, Llc Methods for transmembrane treatment and prevention of otitis media
US8633191B2 (en) * 2004-09-21 2014-01-21 Stephen C. Perry Anti-microbial and anti-fungal shampoo for mammals especially humans and dogs
US20060078580A1 (en) * 2004-10-08 2006-04-13 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
US20060222716A1 (en) * 2005-04-01 2006-10-05 Joseph Schwarz Colloidal solid lipid vehicle for pharmaceutical use
CN101273971A (zh) * 2008-05-09 2008-10-01 绍兴文理学院 抗真菌药物的醇质体制剂及其制备方法
WO2010010470A2 (en) * 2008-07-23 2010-01-28 Tdt, Ltd Methods of administering topical antifungal formulations for the treatment of fungal infections

Also Published As

Publication number Publication date
NI201100152A (es) 2012-03-28
AU2009339445A1 (en) 2011-08-18
EP2393480A1 (en) 2011-12-14
SG173183A1 (en) 2011-09-29
IL214331A0 (en) 2011-09-27
PE20120326A1 (es) 2012-04-20
US20120245107A1 (en) 2012-09-27
WO2010090654A1 (en) 2010-08-12
CO6410285A2 (es) 2012-03-30
MX2011008204A (es) 2011-12-06
CN102368998A (zh) 2012-03-07
KR20110128283A (ko) 2011-11-29
JP2012516889A (ja) 2012-07-26
CA2751412A1 (en) 2010-08-12
RU2011136624A (ru) 2013-03-10
ZA201105758B (en) 2013-01-30
CR20110409A (es) 2011-11-02
ECSP11011246A (es) 2011-11-30
US20100197621A1 (en) 2010-08-05

Similar Documents

Publication Publication Date Title
BRPI0924302A2 (pt) métodos de reduzir a proliferação e a viabilidade de agentes microbianos
SMT201600319B (it) Metodi di selezione e amplificazione di polinucleotidi
BRPI1006537A2 (pt) método e artigo
BR112013001592A2 (pt) artigo e método
BR112012025097A2 (pt) questão e resposta de conversação
DK3040076T3 (da) Sammensætning omfattende et ikke-peptid-antibiotikum og cysteamin
BRPI1010079A2 (pt) composição e artigo
BR112013010847A2 (pt) artigo e método
FI20085334A0 (fi) Harjoitusmenetelmä ja -järjestelmä
BR112012002247A2 (pt) composição e artigo
BR112012027159A2 (pt) estrutura e método
HK1223925A1 (zh) 醛糖還原酶抑制劑及其用途
EP2529327A4 (en) Improving pre-route and post-route net correlation with defined patterns
BR112013002544A2 (pt) seção de armario e armario
BR112013016641A2 (pt) artigo e método
BR112013009579A2 (pt) método e comprimido
PL2616471T3 (pl) Inhibitory acetyloesterazy pektynowej NOTUM i sposoby ich zastosowania
BRPI1014683A2 (pt) marcador e stent
DK2516435T3 (da) Inhibitorer af AKT-aktivitet
IT1399157B1 (it) Rivestimento autolubrificante e metodo
BR112012023507A2 (pt) unidade de comutação e método relacionado
BRPI1015272A2 (pt) Fermentação
ES1073388Y (es) Armario de cultivo
DK2536591T3 (da) Advarselslysanordning; komponenter; og fremgangsmåder
BR112013008812A2 (pt) composição e método

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.